Skip to main content

Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors

Surgery Today volume 49, pages 460–466 (2019)Cite this article

Abstract

Rectal gastrointestinal stromal tumor (GIST) is a rare entity. Thus, its clinical features have not been well documented, and optimal treatment strategies have not been established. Surgery for rectal GISTs may be difficult because they are often large in size. In addition, rectal GISTs were found to be associated with high rates of local recurrence, regardless of the surgical procedure, before imatinib was introduced in the early 2000s. Since the introduction of imatinib therapy, accumulating evidence suggests that neoadjuvant imatinib therapy may improve the outcomes of rectal GIST treatment. Neoadjuvant imatinib therapy for rectal GISTs offers a number of potential benefits, including tumor downsizing, reduction in mitotic activity, reduced morbidity, and a reduced risk of recurrence. Less radical procedures may allow for the preservation of the anal sphincter and avoidance of a permanent colostomy. This review summarizes the current status and future perspectives of neoadjuvant imatinib therapy for the treatment of rectal GISTs.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999;30:1213–20.

    Article  CAS  PubMed  Google Scholar 

  2. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100:162–8.

    Article  Google Scholar 

  3. Tielen R, Verhoef C, van Coevorden F, Reyners AK, van der Graaf WT, Bonenkamp JJ, et al. Surgical management of rectal gastrointestinal stromal tumors. J Surg Oncol. 2013;107:320–3.

    Article  CAS  PubMed  Google Scholar 

  4. Changchien CR, Wu MC, Tasi WS, Tang R, Chiang JM, Chen JS, et al. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. Dis Colon Rectum. 2004;47:1922–9.

    Article  PubMed  Google Scholar 

  5. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol. 2001;25:1121–33.

    Article  CAS  PubMed  Google Scholar 

  6. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.

    Article  PubMed  PubMed Central  Google Scholar 

  7. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.

    Article  PubMed  Google Scholar 

  9. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, Gronchi A, et al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. Ann Surg Oncol. 2013;20:586–92.

    Article  PubMed  Google Scholar 

  11. Wilkinson MJ, Fitzgerald JE, Strauss DC, Hayes AJ, Thomas JM, Messiou C, et al. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib. Br J Surg. 2015;102:965–71.

    Article  CAS  PubMed  Google Scholar 

  12. Pai VD, Demenezes JL, Patil PS, Saklani AP. Multimodality therapy of rectal gastrointestinal stromal tumors in the era of imatinib-an indian series. J Gastrointest Oncol. 2016;7:262–8.

    PubMed  PubMed Central  Google Scholar 

  13. Cavnar MJ, Wang L, Balachandran VP, Antonescu CR, Tap WD, Keohan M, et al. Rectal gastrointestinal stromal tumor (GSIT) in the era of imatinib: organ preservation and improved oncologic outcome. Ann Surg Oncol. 2017;24:3972–80.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–6.

    Article  CAS  PubMed  Google Scholar 

  15. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.

    Article  CAS  PubMed  Google Scholar 

  16. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, et al. Update of phase i study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2002;38:83–7.

    Article  Google Scholar 

  17. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34.

    Article  CAS  PubMed  Google Scholar 

  18. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC soft tissue and bone sarcoma group phase II study. Eur J Cancer. 2003;39:2006–11.

    Article  CAS  PubMed  Google Scholar 

  19. Lo SS, Papachristou GI, Finkelstein SD, Conroy WP, Schraut WH, Ramanathan RK. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case. Dis Colon Rectum. 2005;48:1316–19.

    Article  PubMed  Google Scholar 

  20. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol. 2009;35:739–45.

    Article  CAS  PubMed  Google Scholar 

  21. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Mandala M, Pezzica E, Tamborini E, Guerra U, Lagonigro SM, Forloni B, et al. Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome. Eur J Gastroenterol Hepatol. 2007;19:711–3.

    Article  CAS  PubMed  Google Scholar 

  23. Ebihara Y, Okushiba S, Kawarada Y, Kitashiro S, Katoh H, Kondo S. Neoadjuvant imatinib in a gastrointestinal stromal tumor of the rectum: report of a case. Surg Today. 2008;38:174–7.

    Article  PubMed  Google Scholar 

  24. Fujimoto Y, Akiyoshi T, Konishi T, Nagayama S, Fukunaga Y, Ueno M. Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum. Int J Colorectal Dis. 2014;29:111–6.

    Article  PubMed  Google Scholar 

  25. Nozawa H, Kanazawa T, Tanaka T, Takahashi M, Ishihara S, Sunami E, et al. Laparoscopic resection of a gastrointestinal stromal tumor of the lower rectum in a patient with coronary artery disease following long-term neoadjuvant imatinib treatment and anticoagulation therapy. World J Surg Oncol. 2014;12:211.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ueki T, Nagayoshi K, Manabe T, Maeyama R, Yokomizo A, Yamamoto H, et al. Laparoscopic en bloc excision of gastrointestinal stromal tumors of the rectum after neoadjuvant imatinib therapy: anteriorly extended intersphincteric resection combined with partial resection of the prostate. Tech Coloproctol. 2015;19:247–51.

    Article  CAS  PubMed  Google Scholar 

  27. Nahas CS, Nahas SC, Marques CF, Schmerling R, Bustamante-Lopez LA, Ribeiro U, et al. Gastrointestinal stromal tumor of the rectum treated with neoadjuvant Imatinib followed by transanal endoscopic microsurgery. Arq Bras Cir Dig. 2015;28:87–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Kyo K, Azuma M, Okamoto K, Nishiyama M, Shimamura T, Maema A, et al. Neoadjuvant imatinib treatment and laparoscopic anus-preserving surgery for a large gastrointestinal stromal tumor of the rectum. World J Surg Oncol. 2016;14:68.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Kaneko M, Nozawa H, Emoto S, Murono K, Sasaki K, Otani K, et al. Neoadjuvant imatinib therapy followed by intersphincteric resection for low rectal gastrointestinal stromal tumors. Anticancer Res. 2017;37:5155–60.

    Article  CAS  PubMed  Google Scholar 

  30. Machlenkin S, Pinsk I, Tulchinsky H, Ziv Y, Sayfan J, Duek D, et al. The effect of neoadjuvant imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. Colorectal Dis. 2011;13:1110–5.

    Article  CAS  PubMed  Google Scholar 

  31. Wang JP, Wang T, Huang MJ, Wang L, Kang L, Wu XJ. The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor. Am J Clin Oncol. 2011;34:314–6.

    Article  CAS  PubMed  Google Scholar 

  32. Sun LF, He JJ, Yu SJ, Xu JH, Wang JW, Li J, et al. Transsacral excision with pre-operative imatinib mesylate treatment and approach for gastrointestinal stromal tumors in the rectum: a report of two cases. Oncol Lett. 2014;8:1455–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Nakamura T, Mitomi H, Onozato W, Sato T, Ikeda A, Naito M, et al. Laparoscopic resection of a gastrointestinal stromal tumor of the rectum after treatment with imatinib mesylate: report of a case. Surg Today. 2012;42:1096–9.

    Article  PubMed  Google Scholar 

  34. Huynh TK, Meeus P, Cassier P, Bouche O, Lardiere-Deguelte S, Adenis A, et al. Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French sarcoma group. BMC Cancer. 2014;14:156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Liu H, Yan Z, Liao G, Yin H. Treatment strategy of rectal gastrointestinal stromal tumor (GIST). J Surg Oncol. 2014;109:708–13.

    Article  PubMed  Google Scholar 

  36. Wachter N, Worns MA, Dos Santos DP, Lang H, Huber T, Kneist W. Transanal minimally invasive surgery (TAMIS) approach for large juxta-anal gastrointestinal stromal tumour. J Minim Access Surg. 2016;12:289–91.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Hou Y-Y, Zhou Y, Lu SH, Qi WD, Xu C, Hou J, et al. Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor. World J Gastroenterol. 2009;15:1910–3.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hohenberger P, Eisenberg B. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST). Ann Surg Oncol. 2010;17:2585–600.

    Article  PubMed  Google Scholar 

  39. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19:35–8.

    Google Scholar 

  40. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, et al. Soft tissue sarcoma, version 2.2018, NCCN Clinical Pracatice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed 1 May 2018.

  41. Bonvalot S, Eldweny H, Péchoux CL, Vanel D, Terrier P, Cavalcanti A, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol. 2006;13:1596–603.

    Article  CAS  PubMed  Google Scholar 

  42. Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schoffski P, Bauer S, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013;20:2937–43.

    Article  PubMed  Google Scholar 

  43. Kurokawa Y, Yang HK, Cho H, Ryu MH, Masuzawa T, Park SR, et al. Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer. 2017;117:25–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009;16:910–9.

    Article  PubMed  Google Scholar 

  45. Corless CL, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014;32:1563–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–9.

    Article  CAS  PubMed  Google Scholar 

  47. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889–94.

    Article  PubMed  Google Scholar 

  48. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2004;40:689–95.

    Article  CAS  PubMed  Google Scholar 

  49. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093–103.

    Article  CAS  PubMed  Google Scholar 

  50. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the north American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group. J Clin Oncol. 2008;26:5360–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Ann Rev Med. 2012;63:247–58.

    Article  CAS  PubMed  Google Scholar 

  52. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28:1247–53.

    Article  CAS  Google Scholar 

  53. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. 2000;7:705–12.

    Article  CAS  PubMed  Google Scholar 

  54. Yasui M, Tsujinaka T, Mori M, Takahashi T, Nakashima Y, Nishida T. Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data. Surg Today. 2017;47:1188–94.

    Article  CAS  PubMed  Google Scholar 

  55. Baik SH, Kim NK, Lee CH, Lee KY, Sohn SK, Cho CH, et al. Gastrointestinal stromal tumor of the rectum: an analysis of seven cases. Surg Today. 2007;37:455–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This research is supported by Grants-in-Aid for Scientific Research (C: grant number;16K07143, C: grant number;16K07161, C: grant number;17K10620, C: grant number;17K10621, C: grant number;17K10623 and C: grant number;18K07194) from Japan Society for the promotion of Science. This research is supported by the Project for Cancer Research and Therapeutic Evolution P-CREATE, grant number: 18 cm0106502h0003 from the Japan Agency for Medical Research and Development (AMED).

Author information

Affiliations

  1. Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Manabu Kaneko, Shigenobu Emoto, Koji Murono, Hirofumi Sonoda, Masaya Hiyoshi, Kazuhito Sasaki, Yasutaka Shuno, Takeshi Nishikawa, Toshiaki Tanaka, Keisuke Hata, Kazushige Kawai & Hiroaki Nozawa

Authors
  1. Manabu Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigenobu Emoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Murono
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hirofumi Sonoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masaya Hiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhito Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasutaka Shuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takeshi Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toshiaki Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Keisuke Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kazushige Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroaki Nozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manabu Kaneko.

Ethics declarations

Conflict of interest

Manabu Kaneko and the other co-authors have no conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kaneko, M., Emoto, S., Murono, K. et al. Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors. Surg Today 49, 460–466 (2019). https://doi.org/10.1007/s00595-018-1737-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-018-1737-5

Keywords

  • Neoadjuvant therapy
  • Imatinib
  • Gastrointestinal stromal tumor
  • Rectum